AOD 9604 Peptide

AOD 9604 is a synthetic growth hormone (GH) fragment developed to target fat reduction and support weight management. It reproduces the last 16 amino acids (176–191) of GH, known as GH Fragment 176–191, with a tyrosine added at the N-terminus to improve stability. Researchers consider this fragment the lipolytic portion of GH, meaning it may specifically promote fat breakdown without the broader effects of full GH.

Different regions of GH have distinct effects: the N-terminal region may enhance insulin activity, while amino acids 108–129 are linked to growth-promoting responses. AOD 9604 focuses on the fat-burning segment, potentially offering targeted lipolytic benefits.

Overview

Developed in the 1990s, AOD 9604 has been studied for its anti-obesity potential. Lipolysis, the process of breaking down stored fat into glycerol and free fatty acids for energy, is central to its mechanism. The peptide may influence fat cells and lipolytic receptors, especially beta(3)-adrenergic receptors (beta(3)-AR), which are critical in fat metabolism. Studies suggest AOD 9604 may increase the expression of beta(3)-AR RNA, enhancing receptor sensitivity and potentially improving fat breakdown. Importantly, AOD 9604 may promote fat burning without stimulating insulin-like growth factor-1 (IGF-1), which is commonly affected by natural GH.

Chemical Makeup

• Molecular Formula: C78H123N23O23S2
• Molecular Weight: 1815.12 g/mol
• Other Titles: Tyr-hGH Fragment 177–191

Research and Clinical Studies

Lipolytic Activity
Early experiments in obese mice administered AOD 9604 for 14 days showed reduced weight and fat levels. The peptide appeared to increase beta(3)-AR expression in fat cells and enhanced energy expenditure and fat oxidation. Studies with mice lacking lipolytic receptors suggested that AOD 9604’s effects extend beyond receptor expression, emphasizing its role in boosting energy metabolism.

In obese Zucker rats treated for 19 days, AOD 9604 reduced weight by over 50% compared to placebo and increased lipolytic activity in fat tissue without impairing insulin sensitivity.

Obesity Studies in Humans
A 2004 clinical trial with 300 obese participants over 12 weeks reported consistent weight loss. The study also observed minor improvements in cholesterol profiles and glucose tolerance, indicating potential benefits for metabolic health alongside fat reduction.

AOD 9604 is thus recognized as a targeted fat-reducing peptide with promising research-backed effects on lipolysis and body composition.